NewsBenzingaGenmab A/S gibt bekannt, dass Daten aus der Phase-3-Studie LiGeR-HN1 zu Petosemtamab eine Verringerung des Sterberisikos um 50 % bei der Behandlung von Plattenepithelkarzinomen im Kopf-Hals-Bereich zeigen Genmab A/S gibt bekannt, dass Daten aus der Phase-3-Studie LiGeR-HN1 zu Petosemtamab eine Verringerung des Sterberisikos um 50 % bei der Behandlung von Plattenepithelkarzinomen im Kopf-Hals-Bereich zeigen Benzinga 2026.10.28 13:45 (GMT+0) Open on Benzinga Other news Ramp in Talks to Raise at Least $1 Billion at Valuation of Up to $75 Billion How Everyday Investors Are Playing the Nvidia Drama Curve: Fee Conversion Contract Loses $38.2K in Attack, Disabled With Replacement Planned Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript Nvidia Tops Sales Forecast After Huang's Resignation Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares
Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares